Clozapine- and olanzapine-induced Fos expression in the rat medial prefrontal cortex is mediated by β-adrenoceptors

Neuropsychopharmacology

Volumn 23, Issue 2, 2000, Pages 162-169

  Ohashi, Kazuyo ^a   Hamamura, Takashi ^a   Lee, Youmei ^a   Fujiwara, Yutaka ^b   Suzuki, Hiroshi ^a   Kuroda, Shigetoshi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Takaoka Hospital   (Japan)

Author keywords

Adrenergic receptors; Atypical antipsychotics; Clozapine; Fos, Prefrontal cortex; Immediate early genes; Negative symptom; Noradrenaline; Olanzapine; Schizophrenia

Indexed keywords

BETA ADRENERGIC RECEPTOR; CLOZAPINE; NORADRENALIN; OLANZAPINE; PROPRANOLOL; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; GENE EXPRESSION; IMMEDIATE EARLY GENE; IMMUNOHISTOCHEMISTRY; LOCUS CERULEUS; MALE; NEGATIVE SYNDROME; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CELL COUNT; CELL NUCLEUS; CLOZAPINE; LOCUS COERULEUS; MALE; NEURONS; PIRENZEPINE; PREFRONTAL CORTEX; PROPRANOLOL; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA;

EID: 0034042950     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00105-6     Document Type: Article

References (52)

1. Ackenheil M. Clozapine. Pharmacokinetic investigation and biochemical effects in man Psychopharmacology. 99:1989;S32-S37.
2. Ader J.P., Sebens J.B., Korf J. Central levels of noradrenaline, 3-methoxy-4-hydroxyphenylethyleneglycol and cyclic AMP in the rat after activation of locus coeruleus neurons. Influence of single and repeated neuroleptic treatment Psychopharmacology. 70:1980;239-245.
3. Beasley C.M., Tollefson G., Tran P., Sattterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind trial Neuropsychopharmacology. 14:1996;111-123.
4. Bing G., Stone E.A., Zhang Y., Filer D. Immunohistochemical studies of noradrenergic-induced expression of c-fos in the rat CNS. Brain Res. 592:1992;57-62.
5. Bolden C., Cusack B., Richelson E. Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. Eur J Pharmacol. 192:1991;205-206.
6. Breier A., Buchanan R.W., Waltrip R.W. II, Listwak S., Holmes C., Goldstein D.S. The effect of clozapine on plasma norepinephrine. Relationship to clinical efficacy Neuropsychopharmacology. 10:1994;1-7.
7. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96. a.
8. Bymaster F.P., Hemrick-Luecke S.K., Perry K.W., Fuller R.W. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology. 124:1996;87-94. b.
9. Cedarbaum J.M., Aghajanian G.K. Catecholamine receptors on locus coeruleus neurons. Pharmacological characterization Eur J Pharmacol. 44:1977;375-385.
10. Claghorn J., Honigfeld G., Abuzzahab F.S., Steinbook A.R., Tuason V., Klerman G. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol. 7:1987;377-384.
11. Cohen R.M., Aulakh C., McLellan C., Murphy D.L. 6-Hydroxydopamine pretreatment effects on α- and β-adrenergic receptor adaptation to clorgyline. Naunyn-Schmiedeberg's Arch Pharmacol. 329:1985;158-161.
12. Coward D.M. General pharmacology of clozapine. Br J Psychiatry. 160(Suppl 17):1992;5-11.
13. Deutch A.Y., Duman R.S. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex. Cellular localization and pharmacological characterization Neuroscience. 70:1996;377-389.
14. Dragunow M., Faull R. The use of c-fos as a metabolic marker in neuronal pathway tracing. J Neurosci Meth. 29:1989;261-265.
15. Fink-Jensen A., Kristensen P. Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci Lett. 182:1994;115-118.
16. Fink-Jensen A., Ludvigsen T.S., Korsgaard N. The effect of clozapine on Fos protein immunoreactivity in the rat forebrain is not mimicked by the addition of α1-adrenergic or 5HT2 receptor blockade to haloperidol. Neurosci Lett. 194:1995;77-80.
17. Freedman J.E., Aghajanian G.K. Idazoxan (RX 781094) selectively antagonizes α2-adrenoceptors on rat central neurons. Eur J Pharmacol. 105:1984;265-272.
18. Gobert A., Rivet J.M., Audinot V., Newman-Tancredi A., Cistarelli L., Millan M.J. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto-and heteroreceptor-mediated control of release. Neuroscience. 84:1998;413-429.
19. Grant S.J., Bittman K., Benno R.H. Both phasic sensory stimulation and tonic pharmacological activation increase Fos-like immunoreactivity in the rat locus coeruleus. Synapse. 12:1992;112-118.
20. Guo N., Klitenic M.A., Tham C.S., Fibiger H.C. Receptor mechanisms mediating clozapine-induced c-fos expression in the forebrain. Neuroscience. 65:1995;747-756.
21. Hamamura T., Lee Y., Fujiwara Y., Kuroda S. Serotonin 1A receptor agonists induce Fos protein expression in the locus coeruleus of the conscious rat. Brain Res. 759:1997;156-159.
22. Hamilton S.H., Revicki D.A., Genduso L.A., Beasley C.M. Olanzapine versus placebo and haloperidol. Quality of life and efficacy results of the North American double-blind trial Neuropsychopharmacology. 18:1998;41-49.
23. Holes V.R. The anatomy and function of noradrenaline in the mammalian brain. Heal D.J., Marsden C.A. The pharmacology of noradrenaline in the central nervous system. 1990;1-40 Oxford University Press, Oxford.
24. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Arch Gen Psychiatry. 45:1988;789-796.
25. Kurokawa K., Narita M., Koshiya K., Hidaka K., Ohmori J., Satoh K. Effects of YM-43611, a novel dopamine D2-like receptor antagonist, on immediate early gene expression in the rat forebrain. Neuropsychopharmacology. 17:1997;27-33.
26. L'Heureux R., Dennis T., Curet O., Scatton B. Measurement of endogenous noradrenaline release in the rat cerebral cortex in vivo by transcortical dialysis. Effects of drugs affecting noradrenergic transmission J Neurochem. 46:1986;1794-1801.
27. Li X.-M., Perry K.W., Wong D.T., Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology. 136:1998;153-161.
28. Litman R.E., Hong W.W., Weissman E.M., Su T.-P., Potter W.Z., Pickar D. Idazoxan, an α2 antagonist, augments fluphenazine in schizophrenic patients. A pilot study J Clin Psychopharmacol. 13:1993;264-267.
29. Litman R.E., Su T.-P., Potter W.Z., Hong W.W., Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia, comparison with the atypical neuroleptic, clozapine. Br J Psychiatry. 168:1996;571-579.
30. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin 2 pKi values. J Pharmacol Exp Ther. 251:1989;238-246.
31. Parnavelas J.G. Neurotransmitters in the cerebral cortex. Uylings H.B.M., Van Eden C.G., De Bruin J.P.C., Corner M.A., Feenstra M.G.P. The Prefrontal Cortex. Progress in Brain Research. Vol. 85. 1990;13-29 Elsevier, Amsterdam.
32. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd ed:1986;Academic Press, Sydney.
33. Picker D., Owen R.R., Litman R.E., Konicki P.E., Gutierrez R., Rapaport M.H. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine Arch Gen Psychiatry. 49:1992;345-353.
34. Ramirez O.A., Wang R.Y. Locus coeruleus norepinephrine-containing neurons. Effects produced by acute and subchronic treatment with antipsychotic drugs and amphetamine Brain Res. 362:1986;165-170.
35. Rao M.L., Moller H.J. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. Neuropsychobiology. 30:1994;160-172.
36. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain. Contrasting effects of haloperidol and clozapine Neuroscience. 46:1992;315-328.
37. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther. 271:1994;1058-1066.
38. Robertson G.S., Fibiger H.C. Effects of olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacology. 14:1996;105-110.
39. Rollema H., Lu Y., Schmidt A.W., Zorn S.H. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol. 338:1997;R3-R5.
40. Sagar S.M., Sharp F.R., Curran T. Expression of c-fos protein in brain. Metabolic mapping at the cellular level Science. 240:1988;1328-1331.
41. Sebens J.B., Koch T., Ter Horst G.T., Korf J. Olanzapine-induced Fos expression in the rat fore brain; cross-tolerance with haloperidol and clozapine. Eur J Pharmacol. 353:1998;13-21.
42. Sharp F.R., Sagar S.M., Swanson R.A. Metabolic mapping with cellular resolution. c-fos vs. 2-deoxyglucose Crit Rev Neurobiol. 7:1993;205-228.
43. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 347:1990;146-151.
44. Stone E.A., Zhang Y. Adrenoceptor antagonists block c-fos response to stress in the mouse brain. Brain Res. 694:1995;279-286.
45. Van Kammen D.P., Van Kammen W.B., Mann L.S., Seppala T., Linnoila M. Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Arch Gen Psychiatry. 43:1986;978-983.
46. Van Tol H.H.M., Bunzow J.R., Guan H.C., Sunahara R.K., Seeman P., Niznik H.B., Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 350:1991;610-614.
47. Van Veldhuizen M.J., Feenstra M.G., Boer G.J. Regional differences in the in vivo regulation of the extracellular levels of noradrenaline and its metabolites in rat brain. Brain Res. 635:1994;238-248.
48. Wan W., Ennulat D.J., Cohen B.M. Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain Res. 688:1995;95-104.
49. Weinberger D.R. Schizophrenia and the frontal lobe. Trends Neurosci. 8:1988;367-370.
50. Weinberger D.R., Berman K.F., Illowsky B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. Arch Gen Psychiatry. 45:1988;609-615.
51. Westerink B.H.C., de Boer P., de Vries J.B., Kruse C.G., Long S.K. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol. 361:1998;27-33.
52. Wolkin A., Sanfilipo M., Wolf A.P., Angrist B., Brodie J.D., Rotrosen J. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry. 49:1992;959-965.